News · 26 weeks58-55%
2025-10-262026-04-19
Mix3290d
- Insider16(50%)
- SEC Filings7(22%)
- Other4(13%)
- Earnings3(9%)
- Leadership1(3%)
- Analyst1(3%)
Latest news
25 items- INSIDERSEC Form 4 filed by Brown Michael Jon4 - DEXCOM INC (0001093557) (Issuer)
- SECSEC Form DEFA14A filed by DexCom Inc.DEFA14A - DEXCOM INC (0001093557) (Filer)
- SECSEC Form DEF 14A filed by DexCom Inc.DEF 14A - DEXCOM INC (0001093557) (Filer)
- SECSEC Form 144 filed by DexCom Inc.144 - DEXCOM INC (0001093557) (Subject)
- PRDexcom Schedules First Quarter 2026 Earnings Release and Conference Call for April 30, 2026 at 4:30 p.m. Eastern TimeDexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2026 financial results after market close on Thursday, April 30, 2026. Management will hold a conference call to review the company's first quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference. To listen to the conference call, please dial (888) 414-4585 (US/Canada) or (646) 960-0331 (International) and use the confirmation ID "9430114" approximately five minutes prior to the s
- SECAmendment: SEC Form SCHEDULE 13G/A filed by DexCom Inc.SCHEDULE 13G/A - DEXCOM INC (0001093557) (Subject)
- ANALYSTDexcom upgraded by Evercore ISI with a new price targetEvercore ISI upgraded Dexcom from In-line to Outperform and set a new price target of $90.00
- INSIDERSEC Form 4 filed by Brown Michael Jon4 - DEXCOM INC (0001093557) (Issuer)
- PRDexcom Showcases Breakthrough Outcomes for People With Type 2 Diabetes and Product Roadmap at ATTD 2026New registry study data shows that long-term use of Dexcom G7 supports weight management and lowers A1C for people with Type 2 diabetes who aren't on insulin therapy1, reinforcing the need to broaden CGM access beyond insulin-treated populations. During its symposium on Thursday, March 12, Dexcom will share upcoming product features across its global portfolio. Two in-booth, expert-led presentations on Thursday, March 12, and Friday, March 13 will showcase the first consensus‑based CGM competency framework to give healthcare professionals a clear, role‑aligned structure for delivering confident, consistent CGM support.2 DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose
- INSIDEREVP, Chief Financal Officer Sylvain Jereme M was granted 48,774 shares and covered exercise/tax liability with 18,950 shares, increasing direct ownership by 24% to 153,292 units (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDERExecutive Chair Sayer Kevin R was granted 32,749 shares and covered exercise/tax liability with 32,498 shares, increasing direct ownership by 0.06% to 409,241 units (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDEREVP, Chief Legal Officer Brown Michael Jon was granted 39,019 shares and covered exercise/tax liability with 23,325 shares, increasing direct ownership by 16% to 114,604 units (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDEREVP, Chief HR Officer Stern Sadie was granted 39,019 shares and covered exercise/tax liability with 17,199 shares, increasing direct ownership by 20% to 131,510 units (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDERPresident, CEO, and Director Leach Jacob Steven covered exercise/tax liability with 19,757 shares and was granted 104,516 shares, increasing direct ownership by 25% to 421,810 units (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDEREVP, Chief Commercial Officer Coleman Jon was granted 43,897 shares, increasing direct ownership by 64% to 112,635 units (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- SECDexCom Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - DEXCOM INC (0001093557) (Filer)
- INSIDERDirector Osterloh Albert Frederick Iv was granted 7,061 shares (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDERSEC Form 3 filed by new insider Osterloh Albert Frederick Iv3 - DEXCOM INC (0001093557) (Issuer)
- SECDexCom Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - DEXCOM INC (0001093557) (Filer)
- PRDexcom Appoints Rick Osterloh to Board of DirectorsDexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Rick Osterloh to its Board of Directors, effective February 26, 2026. Mr. Osterloh is a highly accomplished technology executive with more than 20 years of leadership experience across consumer hardware, platform strategy and large-scale product operations. He currently serves as Senior Vice President, Platforms & Devices at Google, where he leads a unified group spanning the company's portfolio of advanced consumer technologies. This includes Android, Google Play, Chrome, and Google's Devices and Services Portfolio—Pixel phones, Google Nest smart home devices, and Fitbit wearables. Und
- PRDexcom Announces Upcoming Conference PresentationDexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the 47th Annual Raymond James Institutional Investors Conference on Monday, March 2, 2026. The live presentation is scheduled to begin at approximately 1:05 PM EST and will be concurrently webcast. Links to the webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com and will be archived there for future reference. About DexCom, Inc. Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transf
- INSIDERDirector Heller Bridgette P sold $68,826 worth of shares (1,012 units at $68.01), decreasing direct ownership by 4% to 26,019 units (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- SECSEC Form 10-K filed by DexCom Inc.10-K - DEXCOM INC (0001093557) (Filer)
- SECDexCom Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - DEXCOM INC (0001093557) (Filer)
- PRDexcom Reports Fourth Quarter and Fiscal Year 2025 Financial ResultsDexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights: Revenue grew 13% year-over-year to $1.260 billion on a reported basis and 12% year-over-year on an organic1 basis. U.S. revenue grew 11% and international revenue grew 18% on a reported basis and 15% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $323.0 million or 25.6% of revenue, an increase of 860 basis points compared to the fourth quarter of 2024. Non-GAAP operating income* of $331.5 million or 26.3% of reported revenue, an increase of 750 basis points compared to the fourth